A Systematic Review and Meta-Analysis of the Effects of Statin Therapy on Heart Transplantation.

IF 1.4 Q4 PHARMACOLOGY & PHARMACY Reviews on recent clinical trials Pub Date : 2024-01-01 DOI:10.2174/0115748871301446240513093612
Hossein Mardani-Nafchi, Seyed Mahmoud Reza Hashemi Rafsanjani, Saeid Heidari-Soureshjani, Saber Abbaszadeh, Babak Gholamine, Nasrollah Naghdi
{"title":"A Systematic Review and Meta-Analysis of the Effects of Statin Therapy on Heart Transplantation.","authors":"Hossein Mardani-Nafchi, Seyed Mahmoud Reza Hashemi Rafsanjani, Saeid Heidari-Soureshjani, Saber Abbaszadeh, Babak Gholamine, Nasrollah Naghdi","doi":"10.2174/0115748871301446240513093612","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Most of the mortality after Heart Transplantation (HT) is attributed to severe cardiac allograft vasculopathy (CAV) and rejection.</p><p><strong>Objectives: </strong>This meta-analysis aimed to investigate the effects of postoperative statin therapy on outcomes (mortality, rejection, and CAV in HT patients).</p><p><strong>Methods: </strong>This systematic review and meta-analysis was performed on publications between 1980 and October 2023 in Web of Science, Scopus, PubMed, Cochrane, Science Direct, Google Scholar, and Embase databases. Heterogeneity was assessed using Chi-square, I2, and forest plots. Publication bias was evaluated using Begg's and Egger's tests. Analyses were performed in Stata 15 with significance at p < 0.05.</p><p><strong>Results: </strong>This meta-analysis included 17 studies comprising 4,627 participants and conducted between 1995 to 2021. Compared to non-users, the odds of mortality were lower among statin users (OR= 0.49, 95% CI: 0.32-0.75, p < 0.001). The odds of CAV were also reduced with statin use (OR= 0.71, 95% CI: 0.53-0.96, p = 0.027). The odds of rejection were not significantly different (OR= 0.69, 95% CI: 0.41-1.15, p = 0.152). However, rejection odds were lower with statins in RCTs (OR= 0.42, 95% CI: 0.21-0.82, p = 0.012) but not in case-control studies (OR= 0.87, 95% CI: 0.49-1.52, p = 0.615). No publication bias was observed with Begg's test, but Egger's test showed possible bias.</p><p><strong>Conclusion: </strong>This meta-analysis found postoperative statin use associated with lower mortality and CAV, but not overall rejection, though RCT subgroup analysis showed decreased rejection with statins. Statin therapy may improve prognosis in HT patients.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"256-266"},"PeriodicalIF":1.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews on recent clinical trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748871301446240513093612","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Most of the mortality after Heart Transplantation (HT) is attributed to severe cardiac allograft vasculopathy (CAV) and rejection.

Objectives: This meta-analysis aimed to investigate the effects of postoperative statin therapy on outcomes (mortality, rejection, and CAV in HT patients).

Methods: This systematic review and meta-analysis was performed on publications between 1980 and October 2023 in Web of Science, Scopus, PubMed, Cochrane, Science Direct, Google Scholar, and Embase databases. Heterogeneity was assessed using Chi-square, I2, and forest plots. Publication bias was evaluated using Begg's and Egger's tests. Analyses were performed in Stata 15 with significance at p < 0.05.

Results: This meta-analysis included 17 studies comprising 4,627 participants and conducted between 1995 to 2021. Compared to non-users, the odds of mortality were lower among statin users (OR= 0.49, 95% CI: 0.32-0.75, p < 0.001). The odds of CAV were also reduced with statin use (OR= 0.71, 95% CI: 0.53-0.96, p = 0.027). The odds of rejection were not significantly different (OR= 0.69, 95% CI: 0.41-1.15, p = 0.152). However, rejection odds were lower with statins in RCTs (OR= 0.42, 95% CI: 0.21-0.82, p = 0.012) but not in case-control studies (OR= 0.87, 95% CI: 0.49-1.52, p = 0.615). No publication bias was observed with Begg's test, but Egger's test showed possible bias.

Conclusion: This meta-analysis found postoperative statin use associated with lower mortality and CAV, but not overall rejection, though RCT subgroup analysis showed decreased rejection with statins. Statin therapy may improve prognosis in HT patients.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
他汀类药物疗法对心脏移植影响的系统性回顾和荟萃分析。
背景:心脏移植术(HT)后的大部分死亡率归因于严重的心脏异体移植血管病变(CAV)和排斥反应:本荟萃分析旨在研究他汀类药物术后治疗对预后(HT 患者的死亡率、排斥反应和 CAV)的影响:本系统综述和荟萃分析针对1980年至2023年10月期间在Web of Science、Scopus、PubMed、Cochrane、Science Direct、Google Scholar和Embase数据库中发表的论文。采用Chi-square、I2和森林图评估异质性。发表偏倚采用 Begg's 和 Egger's 检验进行评估。分析在 Stata 15 中进行,显著性为 p <0.05:这项荟萃分析包括 1995 年至 2021 年间进行的 17 项研究,共有 4627 人参与。与不使用他汀类药物者相比,使用他汀类药物者的死亡几率较低(OR= 0.49,95% CI:0.32-0.75,p < 0.001)。使用他汀类药物也会降低 CAV 的几率(OR= 0.71,95% CI:0.53-0.96,p = 0.027)。发生排斥反应的几率没有明显差异(OR= 0.69,95% CI:0.41-1.15,p = 0.152)。然而,在研究性临床试验中,他汀类药物的排斥几率较低(OR= 0.42,95% CI:0.21-0.82,p = 0.012),但在病例对照研究中则不然(OR= 0.87,95% CI:0.49-1.52,p = 0.615)。Begg检验未发现发表偏倚,但Egger检验显示可能存在偏倚:这项荟萃分析发现,术后使用他汀类药物与较低的死亡率和CAV有关,但与总体排斥反应无关,尽管RCT亚组分析显示他汀类药物可降低排斥反应。他汀类药物治疗可改善高危人群的预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Reviews on recent clinical trials
Reviews on recent clinical trials PHARMACOLOGY & PHARMACY-
CiteScore
3.10
自引率
5.30%
发文量
44
期刊介绍: Reviews on Recent Clinical Trials publishes frontier reviews on recent clinical trials of major importance. The journal"s aim is to publish the highest quality review articles in the field. Topics covered include: important Phase I – IV clinical trial studies, clinical investigations at all stages of development and therapeutics. The journal is essential reading for all researchers and clinicians involved in drug therapy and clinical trials.
期刊最新文献
Unraveling the Mysteries of Alzheimer's Disease Using Artificial Intelligence. Non-alcoholic Wernicke Encephalopathy in a Young Patient with Adenocarcinoma of the Colon: A Case Report and Review of the Literature. The Efficacy of Two Triple Therapy Regimens and One Quadruple Regimen [Omeprazole, Amoxicillin, Metronidazole with Bismuth] in Eradicating Helicobacter Pylori in Patients with Peptic Ulcer: A Randomized Clinical Trial. Ongoing Clinical Trials for Polycystic Ovarian Syndrome (PCOS) Afflicted Infertility in Women: A Narrative Review. Etiology, Recent Advances, and Clinical Trials Data for the Treatment of Angioedema: A Review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1